tgoop.com/startupsi/1847
Last Update:
Proton Intelligence, a Canadian startup, has developed a continuous potassium monitoring device aimed at helping individuals with chronic kidney disease and reducing heart failure risks. The company recently secured $6.95 million in seed funding, with clinical trials underway for a product set to launch in 2025.
The device will be implanted just under the skin and connect to a smartphone app, allowing patients to monitor potassium levels and receive alerts if their levels become unsafe. This innovation aims to reduce the need for in-clinic potassium testing and improve patient management, addressing the significant health risks associated with potassium imbalances.
Co-founders Sahan Ranamukhaarachchi and Victor Cadarso based their startup on extensive research highlighting the dangers of inadequate potassium monitoring. Proton competes with other companies in the sector, claiming their solution offers greater usability and clinical impact. The startup plans to enhance patient care by leveraging data to refine therapies and is supported by various investors, including SOSV and We Venture Capital.
